GILD

Últimas noticias sobre Gilead Sciences (NASDAQ:GILD) Bolsa

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Alphabet

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

GOOG

GOOGL

INTC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: PSX, GOOG, SLB, INTC y GILD.

5 acciones en el foco este viernes: PSX, GOOG, SLB, INTC y GILD

Time magazine

Entertainment

Management

Media

NFLX

PLTR

TSLA

Descubre quiénes son los directores ejecutivos elegidos por Time en 2025 y cómo han transformado sus sectores clave.

Elon Musk lidera CEOs influyentes que transformaron industrias según lista Time 2025

Eli Lilly and Co.

Equities

Government

ABBV

AMGN

FTXH

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump quiere que las farmacéuticas vuelvan a EE. UU. ¿Cómo afectarán sus aranceles a las acciones del sector?

Trump presiona a farmacéuticas con aranceles para forzar regreso a EE. UU.

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

President Donald Trump&#8216;s ongoing tariff policy changes have resulted in persistent market volatility and uncertainty. This has increased investors' appetite for stable, defensive stocks paying steady dividends. Dividend stocks have <a href="https://www.hartfordfunds.com/dam/en/docs/pub/whitepapers/WP106.pdf">contributed</a> significantly to overall market returns during the 1940s, 1960s, and 1970s, when average annual total returns were lower.
About seven months ago, a dividend investor <a href="https://www.reddit.com/r/dividends/comments/1fldncg/finally_hit_300k_goal/">shared</a> his monthly dividend income details and portfolio on r/Dividends — a Reddit discussion board with over 700,000 followers. The income report shared by the investor showed his monthly dividend income was $23,800, with a projected annual dividend income of just over $300,000.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>
The investor, in his mid-50s, said he had about 150 holdings in his portfolio worth roughly $4.4 million. Asked how he was able to accumulate wealth to build such a large portfolio, he said it took him years to reach this milestone:
"Started at $3.50 per hour. Went back to school in my early 30s as did my wife. Definitely no inheritance and student loans to boot. Just 35 years of investing."
The investor said over $2 million of his wealth came from "decades of trading" biotech company Immunomedics, which was <a href="https://www.gilead.com/news/news-details/2020/gilead-sciences-to-acquire-immunomedics">bought</a> by Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) in 2020 for $88 per share.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Let's take a look at some of the biggest holdings of the investor.
BlackRock Science and Technolgy Term Trust
BlackRock Science and Technology Term Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSTZ#NYSE">BSTZ</a>) was the biggest holding of the investor. The closed-end equity fund invests in science and technology companies and also generates income by selling call options on stocks in its portfolio. It has a dividend yield of about 9%.&nbsp;
Nuveen Real Asset Income and Growth Fund
The Nuveen Real Asset Income and Growth Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JRI#NYSE">JRI</a>) invests in companies related to infrastructure projects, facilities, and services, as well as REITs. Among the top holdings of the fund are Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>), Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>), Gaming and Leisure Properties (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>), Simon Property (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) and Omega Healthcare Investors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>).
DoubleLine Income Solutions Fund
DoubleLine Income Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DSL#NYSE">DSL</a>) is a closed-end fund focusing on income-generating fixed-income securities. It yields about 12% and pays monthly.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
Kayne Anderson Energy Infrastructure Fund&nbsp;
The Kayne Anderson Energy Infrastructure Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KYN#NYSE">KYN</a>) invests in midstream, natural gas &amp; LNG infrastructure, and power infrastructure companies. The fund has a dividend yield of over 8%.
Western Asset High Income Opportunity Fund
Another closed-end fund in the portfolio, Western Asset High Income Opportunity Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIO#NYSE">HIO</a>) primarily invests in high-yield corporate debt securities and preferred stocks for income generation and capital appreciation. The fund has a distribution rate of over 10%.&nbsp;
Voya Infrastructure, Industrials and Materials Fund
The Voya Infrastructure, Industrials and Materials Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDE#NYSE">IDE</a>) invests in companies in the infrastructure, industrials and materials sectors. Cisco (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>), Verizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>), Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>), Uber (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and T-Mobile US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) are among the fund's biggest holdings.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

BSTZ

CSCO

GLPI

TMUS

UBER

Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour  —  'Just 35 Years of Investing'

Gilead Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NYSE">GILD</a>) short percent of float has fallen 4.44% since its last report. The company recently reported that it has 21.39 million shares sold short, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Gilead Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745600430_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Gilead Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Gilead Sciences's peer group average for short interest as a percentage of float is 5.92%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Gilead Sciences?

Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on <a href="https://www.benzinga.com/news/global/25/04/45004954/china-reportedly-begins-exempting-key-us-imports-from-tariffs-including-pharma-and-aerospace-parts">U.S.-China trade relations.</a>
President Donald Trump claimed to have held a phone call with President Xi Jinping, yet Chinese officials denied that any talks had taken place.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) extended its rally into a fourth consecutive session, notching its best weekly performance of the year with a 16% gain. On Thursday afternoon, Transportation Secretary Sean Duffy introduced a new regulatory framework for self-driving vehicles, saying it aimed to reduce bureaucratic hurdles and advance toward a unified national standard.
T-Mobile US Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NYSE">TMUS</a>) was the biggest laggard of the day, falling 11%, on track for its worst single-day loss since March 2020. This came despite better-than-expected earnings, as its core wireless business posted slower growth than analysts had projected.
Among sectors, consumer discretionary led gains, buoyed by Tesla's 8% gain, while materials underperformed.
In fixed income, Treasury yields declined for a fourth straight session, underscoring how critical Trump's early-week reassurance — that he would not dismiss Fed Chair Jerome Powell — was for bond market sentiment.
The yield on the 10-year Treasury note dropped 4 basis points to 4.27%, on course for its lowest close since April 8.
In commodities, gold slid 2%, oil held steady at $62 per barrel, and natural gas rose 1% to $3 per million British thermal units, snapping a 10-session losing streak.
In crypto markets, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.2% to $95,000.
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,250.90</td>
<td>+0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,488.71</td>
<td>+0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,908.60</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,942.82</td>
<td colspan="2">-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) flattened at $546.92.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.5% to $399.23.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.2% to $468.61.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $192.79.</li>
<li>The&nbsp;Consumer Discretionary&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 1.1%; the&nbsp;Materials Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
Stocks reacting to earnings report included:
<ul>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>): up 1.7%</li>
<li>T-Mobile US Inc.: down 10.9%</li>
<li>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>): up 2.4%</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>): down 7.2%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): down 3.2%</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>): down 11.0%</li>
<li>Republic Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>): down 0.2%</li>
<li>Digital Realty Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>): up 3.0%</li>
<li>HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>): down 5.2%</li>
<li>Charter Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>): up 10.3%</li>
<li>The Hartford Financial Services Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>): down 1.1%</li>
<li>Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>): down 2.1%</li>
<li>Colgate-Palmolive Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CL#NYSE">CL</a>): up 1.1%</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>): down 7.7%</li>
<li>LyondellBasell Industries N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>): up 0.0%</li>
<li>VeriSign Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>): up 9.1%</li>
<li>Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>): down 2.0%</li>
<li>Carrier Global Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>): down 0.5%</li>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>): down 0.7%</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>): down 11.8%</li>
<li>Principal Financial Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>): down 1.4%</li>
<li>Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>): down 6.0%</li>
<li>Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): down 4.7%</li>
</ul>
Read now: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45009066/goldman-sachs-upgrades-charles-schwab-to-buy-one-of-the-best-earnings-growth-outlooks-analyst-says">Goldman Sachs Upgrades Charles Schwab To Buy: &#8216;One Of The Best Earnings Growth Outlooks,&#8217; Analyst Says</a></li>
</ul>
Photo: Shutterstock

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Econ #s

Economics

Tech

ETFs

$BTC

CARR

CHTR

SPDR Dow Jones Industrial Average ETF Trust

ERIE

VRSN

Select Sector SPDR-Consumer Discretionary

Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and lowers the price target from $132 to $125.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Gilead Sciences, Lowers Price Target to $125

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Overweight and raises the price target from $130 to $135.

Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $135

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Gilead Sciencesto Hold

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Friday.
Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) fell sharply in today's pre-market trading following a <a href="https://in.benzinga.com/news/earnings/25/04/44996051/skechers-stock-falls-on-q1-revenue-miss-details">first-quarter revenue miss</a>.
Skechers reported quarterly earnings of $1.34 per share, which beat the analyst consensus estimate of $1.17. Quarterly revenue came in at $2.41 billion, which missed the consensus estimate of $2.43 billion.
Skechers shares dipped 7.2% to $46.82 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>TMC the metals company Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) dipped 7.3% to $3.42 in pre-market trading.</li>
<li>Azul S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) fell 7.1% to $1.05 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) declined 5.9% to $86.70 in pre-market trading after the company issued second-quarter sales guidance below estimates.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) fell 5.7% to $20.27 in pre-market trading. Intel reported upbeat first-quarter financial results, but issued weak outlook for the second quarter. Intel said it expects second-quarter revenue to be in the range of $11.2 billion to $12.4 billion versus estimates of $12.84 billion. The company anticipates a second-quarter earnings loss of 32 cents per share versus estimates for a loss of 16 cents per share.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) declined 5.5% to $247.83 in pre-market trading following first-quarter results.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) dipped 4.7% to $11.95 in pre-market trading.</li>
<li>Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) fell 3.8% to $102.14 in today's pre-market trading after the company posted mixed first-quarter results. Gilead Sciences also lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to a range of $5.65 to $6.05 per share, versus the $6.21 estimate.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) slipped 3.8% to $34.24 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Movers

AZUL

Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session

WIIM

Gilead Sciences shares are trading lower after the company reported worse-than-expected Q1 sales results and cut its FY25 EPS guidance.

Shares of Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/cour">better-than-expected first-quarter financial results.</a>
Coursera reported quarterly earnings of 12 cents per share which beat the analyst consensus estimate of 8 cents per share. The company reported quarterly sales of $179.30 million which beat the analyst consensus estimate of $175.40 million.
Coursera shares jumped 7.5% to $8.28 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) rose 72.9% to $0.0699 in pre-market trading after dipping around 33% on Thursday.</li>
<li>The OLB Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLB#NASDAQ">OLB</a>) surged 33.4% to $1.91 in pre-market trading after gaining 14% on Thursday.</li>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) gained 32.5% to $1.13 in pre-market. Odyssey Marine Exploration shares jumped around 100% on Thursday following a Reuters report indicating President Trump is expected to sign an executive order to advance the deep sea mining industry.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) surged 27.7% to $1.11 in pre-market trading after the company posted a narrower-than-expected quarterly loss.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) gained 25.4% to $0.3838 in pre-market trading after the company announced it entered $20 million share purchase agreement with Alumni Capital.</li>
<li>Westrock Coffee Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) gained 18.4% to $6.79 in pre-market trading.</li>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) jumped 18.2% to $29.32 in pre-market trading. Cantor Equity Partners shares surged 50% on Thursday after entering into a business combination agreement with Twenty One Capital.</li>
<li>Jayud Global Logistics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) rose 17.3% to $0.2640 in pre-market trading after falling over 15% on Thursday.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) gained 5.5% to $168.07 in pre-market trading after the reported better-than-expected first-quarter financial results after the closing bell on Thursday. Alphabet announced a 5% increase to the dividend with the quarterly payout going to 21 cents per share. The company also announced the Board of Directions authorized a $70 billion share repurchase plan on April 23.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Wag! Group Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 25.2% to $0.1137 in pre-market trading after jumping around 38% on Thursday.</li>
<li>Precipio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) declined 22.6% to $5.20 in pre-market trading after falling more than 12% on Thursday.</li>
<li>BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) shares dipped 17.9% to $4.95 in pre-market trading after the company announced the pricing of $13.8 million public offering.</li>
<li>Jiuzi Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares tumbled 17.3% to $1.95 in pre-market trading after dipping 68% on Thursday.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) fell 13.6% to $0.5699 in pre-market trading after gaining 14% on Thursday.</li>
<li>Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) fell 12.4% to $5.01 in pre-market trading after gaining 5% on Thursday.</li>
<li>Tvardi Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVRD#NASDAQ">TVRD</a>) shares fell 9.5% to $16.11 in pre-market trading.</li>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) dipped 7.2% to $46.82 in pre-market trading following a first-quarter revenue miss.</li>
<li>Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) fell 5.7% to $20.27 in pre-market trading. Intel reported upbeat first-quarter financial results, but issued weak outlook for the second quarter. Intel said it expects second-quarter revenue to be in the range of $11.2 billion to $12.4 billion versus estimates of $12.84 billion. The company anticipates a second-quarter earnings loss of 32 cents per share versus estimates for a loss of 16 cents per share.</li>
<li>Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) fell 3.8% to $102.14 in today's pre-market trading after the company posted mixed first-quarter results. Gilead Sciences also lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to a range of $5.65 to $6.05 per share, versus the $6.21 estimate.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/25/04/45001899/alphabet-intel-and-3-stocks-to-watch-heading-into-friday">Alphabet, Intel And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

AGMH

AZTR

BCTX

COUR

CPOP

JZXN

OMEX

PRPO

SHCO

TVRD

WEST

Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) to report a quarterly loss at 72 cents per share on revenue of $31.33 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Phillips 66 shares fell 0.7% to $103.99 in after-hours trading.</li>
<li>Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported better-than-expected first-quarter financial results after the closing bell on Thursday. Alphabet announced a 5% increase to the dividend with the quarterly payout going to 21 cents per share. The company also announced the Board of Directions authorized a $70 billion share repurchase plan on April 23. Alphabet shares gained 4.8% to $166.95 in the after-hours trading session.</li>
<li>Analysts are expecting Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) to post quarterly earnings at 74 cents per share on revenue of $8.59 billion. The company will release earnings before the markets open. SLB shares gained 0.5% to $35.09 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) reported upbeat first-quarter financial results, but issued weak outlook for the second quarter. Intel said it expects second-quarter revenue to be in the range of $11.2 billion to $12.4 billion versus estimates of $12.84 billion. The company anticipates a second-quarter earnings loss of 32 cents per share versus estimates for a loss of 16 cents per share. Intel shares tumbled 5.1% to $20.40 in the after-hours trading session.</li>
<li>Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) posted mixed first-quarter results after Thursday&#8217;s closing bell. Gilead Sciences also lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to a range of $5.65 to $6.05 per share, versus the $6.21 estimate. Gilead Sciences shares fell 3.3% to $102.65 in the after-hours trading session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields"> </a>
<ul>
<li><a href="https://www.benzinga.com/25/04/44977071/wall-streets-most-accurate-analysts-weigh-in-on-3-materials-stocks-with-over-7-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Alphabet, Intel And 3 Stocks To Watch Heading Into Friday

Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) released its first-quarter results after Thursday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/b44994576/gilead-sciences-announces-first-quarter-2025-financial-results"> from the report. </a>
The Details: Gilead Sciences reported quarterly earnings of $1.81 per share, which beat the analyst consensus estimate of $1.76. Quarterly revenue came in at $6.67 billion, which missed the analyst consensus estimate of $6.77 billion and is a decrease from revenue of $6.69 billion year-over-year.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, the company reported: 
<ul>
<li>HIV product sales increased 6% to $4.6 billion in the first quarter of 2025 compared to the same period in 2024, primarily driven by higher average realized price and demand.</li>
<li>Liver Disease portfolio sales increased 3% to $758 million in the first quarter of 2025 compared to the same period in 2024. This was primarily driven by increased demand in products for primary biliary cholangitis, chronic hepatitis B virus and chronic hepatitis delta virus, partially offset by lower average realized price for chronic hepatitis C virus products.</li>
<li>Veklury sales decreased 45% to $302 million in the first quarter of 2025 compared to the same period in 2024, primarily driven by lower rates of COVID-19-related hospitalizations across regions.</li>
<li>Cell Therapy&nbsp;product sales decreased 3% to $464 million in the first quarter 2025 compared to the same period in 2024.</li>
</ul>
&#8220;Gilead had a strong start to the year driven by excellent commercial and clinical execution along with disciplined expense management,&#8221; said Daniel O&#8217;Day, Gilead&#8217;s CEO.
&#8220;Our base business grew 4% year-over-year, primarily led by Biktarvy&#8217;s continued strength, and we announced positive topline Phase 3 results for Trodelvy plus pembrolizumab in first line PD-L1+ metastatic triple negative breast cancer,&#8221; O&#8217;Day added. 
Outlook:&nbsp;Gilead Sciences lowered its fiscal 2025 earnings guidance from a range of $5.95 to $6.35 per share to&nbsp;a range of $5.65 to $6.05&nbsp;per share, versus the $6.21&nbsp;estimate. 
GILD Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Gilead Sciences stock was down 3.34% after hours at $102.70 on Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

After-Hours Center

General

Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) lowers FY2025 GAAP EPS guidance from $5.95-$6.35 to $5.65-$6.05 vs $6.21 analyst estimate..

Guidance

Gilead Sciences Lowers FY2025 GAAP EPS Guidance from $5.95-$6.35 to $5.65-$6.05 vs $6.21 Est

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) affirms FY2025 Adj EPS guidance from $7.70-$8.10 to $7.70-$8.10 vs $7.86 analyst estimate. Affirms FY2025 sales outlook from $28.20 billion-$28.60 billion to $28.20 billion-$28.60 billion vs $28.72 billion estimate.

Gilead Sciences Affirms FY2025 Adj EPS Guidance of $7.70-$8.10 vs $7.86 Est; Affirms FY2025 Product Sales Guidance of $28.20B-$28.60B vs $28.72B Est

Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) reported quarterly earnings of $1.81 per share which beat the analyst consensus estimate of $1.76 by 2.84 percent. This is a 237.12 percent increase over losses of $(1.32) per share from the same period last year. The company reported quarterly sales of $6.67 billion which missed the analyst consensus estimate of $6.77 billion by 1.57 percent. This is a 0.28 percent decrease over sales of $6.69 billion the same period last year.

Earnings Beats

Earnings Misses

Gilead Sciences Q1 Adj. EPS $1.81 Beats $1.76 Estimate, Sales $6.67B Miss $6.77B Estimate

U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade <a href="https://www.benzinga.com/markets">tensions boosts risk sentiment.</a>
Positive quarterly results and robust guidance from U.S. firms is fueling hopes the economy can weather the ongoing tariff headwinds and avoid a recession.
Meanwhile, signs of a potential thaw in the U.S.-China trade conflict emerged, with the White House reportedly considering exceptions for certain Chinese auto parts.
At midday trading in New York, the Nasdaq 100 surged 2.2%, climbing above the 19,000 mark for the first time in two weeks. The S&amp;P 500 advanced 1.5%, while the Dow Jones Industrial Average underperformed, rising 0.9%.
Technology stocks broadly outperformed, with strength concentrated in the Magnificent Seven and the semiconductor space.
Among major movers, ServiceNow Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NASDAQ">NOW</a>) soared 15% after reporting results that beat Wall Street expectations and issuing bullish forward guidance. In contrast, shares of International Business Machines Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) slumped 8% as the tech giant showed lower-than-expected non-GAAP earnings. 
In the consumer staples sector, Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) dropped more than 5% after missing revenue estimates.
Treasury yields continued to ease, with yields on the 10-year Treasury down 5 basis points to 4.33%. 
Gold rebounded modestly after suffering a 2.7% slide on Wednesday. Natural gas prices extended their losing streak, plunging 4.9% and heading for a tenth consecutive negative session. 
In the crypto market, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) eased 0.5% to trade at $93,300. 
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,095.73</td>
<td>2.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,456.36</td>
<td>1.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,943.95</td>
<td>1.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>39,944.47</td>
<td>0.9%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:15 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.5% up to $543.71.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.9% to $399.51.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 2.1% to $464.72.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rallied 1.5% to $193.08.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 3%; the&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>) lagged, down 0.8%.</li>
</ul>
<h2 class="wp-block-heading">Thursday&#8217;s Stock Movers</h2>
Stocks reacting to earnings included: 
<ul>
<li>Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>): up 0.6%</li>
<li>O'Reilly Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>): down 3.1%</li>
<li>Raymond James Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>): up 0.7%</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>): down 6.4%</li>
<li>Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>): up 6.0%</li>
<li>FirstEnergy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FE#NYSE">FE</a>): up 0.4%</li>
<li>ServiceNow, Inc. up 14.9%</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>): up 5.5%</li>
<li>ResMed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMD#NYSE">RMD</a>): up 10.0%</li>
<li>Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): up 3.6%</li>
<li>International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>): down 7.6%</li>
<li>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>): up 3.6%</li>
<li>Rollins, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>): up 1.2%</li>
<li>United Rentals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URI#NYSE">URI</a>): up 8.9%</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>): down 3.0%</li>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 7.1%</li>
<li>Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>): up 5.2%</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>): down 9.7%</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>): up 2.3%</li>
<li>PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>): down 4.1%</li>
<li>CBRE Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 2.5%</li>
<li>Entergy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETR#NYSE">ETR</a>): up 0.4%</li>
<li>The Procter &amp; Gamble Company: down 5.3%</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>): down 0.2%</li>
<li>Southwest Airlines Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>): down 0.2%</li>
<li>Valero Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>): down 1.8%</li>
<li>Comcast Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>): down 5.3%</li>
<li>Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>): up 2.1%</li>
<li>Willis Towers Watson Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTW#NASDAQ">WTW</a>): down 5.2%</li>
<li>Tractor Supply Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>): down 4.8%</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>): up 16.1%</li>
<li>CMS Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMS#NYSE">CMS</a>): up 2.3%</li>
<li>Xcel Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>): down 1.8%</li>
<li>CenterPoint Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>): up 1.8%</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>): down 10.7%</li>
<li>PG&amp;E Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>): down 0.8%</li>
<li>Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>): down 0.6%</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>): up 5.5%</li>
<li>Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>): down 0.6%</li>
<li>Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>): down 0.4%</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>): up 0.4%</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>): down 6.1%</li>
<li>Dover Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOV#NYSE">DOV</a>): up 1.8%</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 2.2%</li>
<li>Ameriprise Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>): down 0.2%</li>
<li>Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>): down 16.4%</li>
<li>The Interpublic Group of Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>): up 3.4%</li>
<li>Allegion plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLE#NYSE">ALLE</a>): up 9.7%</li>
<li>Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>): down 3.1%</li>
</ul>
Stocks slated to report earnings after the bell include T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>), VeriSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>), Eastman Chemical Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), Principal Financial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFG#NASDAQ">PFG</a>), Physicians Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), The Hartford Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIG#NYSE">HIG</a>), Weyerhaeuser Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>), Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>), Digital Realty Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>), Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>), Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>).
Read also: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44985682/apples-ai-delays-rising-cost-pressures-trigger-price-target-cut-from-bank-of-america">Apple AI Delays, Rising Cost Pressures Trigger Price Target Cut From Bank Of America</a></li>
</ul>
Photo: Shutterstock

Analyst Color

ALLE

CBRE

CMCSA

LRCX

NDAQ

ORLY

POOL

TSCO

Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?

BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) confirmed on Thursday that it has sustained a complete resolution of the lung metastasis, first reported <a href="https://www.benzinga.com/pressreleases/25/02/g43430846/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots" target="_blank" rel="noopener">in February 2025</a>, two months after the initial treatment in the ongoing Phase 1/2 Bria-OTS study.
The latest data, at four months, also demonstrate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44975836/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots" rel="noreferrer noopener">stable disease elsewhere</a>.
Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer (MBC) patient following 2 months of therapy. It was confirmed at 4 months of therapy&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">(axial and coronal views)</a>.
The company said the lesion in the patient&#8217;s right lung is undetectable after two months and confirmed resolved at 4 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44968420/amentum-offloads-hardware-unit-to-focus-on-critical-services-inks-360-million-deal-with-lockheed-martin" rel="noreferrer noopener">Amentum Offloads Hardware Unit To Focus On Critical Services, Inks $360 Million Deal With Lockheed Martin</a>
The updated images supersede those previously reported.
The patient, a 78-year-old woman with metastatic breast cancer (hormone receptor-positive, HER2 negative), had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study.
At enrollment on November 21, 2024, she had extensive metastases, including bone, lymph node and lung involvement. 
Following Bria-OTS intradermal injections every 2 weeks for six weeks (4 total doses) and subsequent dosing every 3 weeks, the lung metastasis completely resolved with stable disease elsewhere.
Bria-OTS is a personalized off-the-shelf immunotherapy currently under investigation in a Phase 1/2a dose escalation study in metastatic recurrent breast cancer.
The Phase 1/2a trial in metastatic breast cancer is a dose escalation study initially evaluating the safety and efficacy of Bria-OTS as monotherapy. Bria-OTS will follow it in combination with an immune checkpoint inhibitor.
In April, BriaCell Therapeutics released new survival data from its Phase 2 study of Bria-IMT plus checkpoint inhibitors (CPI), which outperformed ADC drugs in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients.
The survival data of 25 patients (17.3 months) exceeded those of the current ADC standard of care Gilead Sciences Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Trodelvy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44835062/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer" rel="noreferrer noopener">(sacituzumab govitecan)&nbsp;(14.4 months)</a>.
The survival data for the Bria-IMT regimen + immune checkpoint inhibitor in triple-negative breast cancer (TNBC) was similar to Trodelvy&nbsp;but still markedly higher (70%) than those of chemotherapy.
On Tuesday, BriaCell Therapeutics announced that its ongoing pivotal Phase 3 clinical study for Bria-IMT plus an immune checkpoint inhibitor versus a physician&#8217;s choice in advanced metastatic breast cancer has obtained consent from over 100 patients and has enrolled more than 75.
BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report topline data as early as H1-2026.
In February, the company closed a public offering of 762,500 shares at $4.00 per share, raising $3.05 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43509465/briacell-therapeutics-announces-closing-of-public-offering" rel="noreferrer noopener">in gross proceeds</a>.
Price Action: BCTX stock is up 65% at $8.96 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44968005/whats-going-on-with-chinese-ev-manufacturer-nio-stock-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Chinese EV Manufacturer NIO Stock On Wednesday?</a></li>
</ul>
Photo: Shutterstock

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

ADXN

ALEX

AMAL

AMBP

APOG

APPF

BAFN

BCPC

BELFA

BELFB

BFST

BHLB

BWMX

CIVB

CNOB

CUBI

CURB

DAIO

DGICA

DGICB

FARO

FBIZ

FCFS

FCNCA

FFBC

FRME

GBCI

GNFT

HELE

HFWA

IBCP

INDV

ITGR

KNSL

KRNY

LADR

LYTS

MBLY

MGRC

MMSI

MOFG

Earnings Scheduled For April 24, 2025

In the current market session, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) share price is at $107.00, after a 1.41% increase. Moreover, over the past month, the stock decreased by 2.64%, but in the past year, went up by 62.98%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745445621_0.png" alt="Past Year Chart" />

<h3>A Look at Gilead Sciences P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 57.02 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 277.66. Shareholders might be inclined to think that Gilead Sciences Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745445621_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

P/E Ratio Insights for Gilead Sciences

Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.
Looking at options history for Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 54% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $175,223 and 6, calls, for a total amount of $302,880.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $115.0 for Gilead Sciences over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Gilead Sciences options trades today is 828.82 with a total volume of 4,116.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Gilead Sciences's big money trades within a strike price range of $60.0 to $115.0 over the last 30 days.
<h3>Gilead Sciences 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745431276_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.4</td>
<td>$3.3</td>
<td>$3.3</td>
<td>$110.00</td>
<td>$78.2K</td>
<td>2.2K</td>
<td align="right">261</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$4.0</td>
<td>$3.7</td>
<td>$4.0</td>
<td>$104.00</td>
<td>$62.8K</td>
<td>1.0K</td>
<td align="right">159</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$2.6</td>
<td>$108.00</td>
<td>$61.6K</td>
<td>18</td>
<td align="right">241</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$1.2</td>
<td>$1.03</td>
<td>$1.06</td>
<td>$60.00</td>
<td>$51.5K</td>
<td>120</td>
<td align="right">480</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$1.33</td>
<td>$1.24</td>
<td>$1.33</td>
<td>$108.00</td>
<td>$39.9K</td>
<td>155</td>
<td align="right">312</td>
</tr>
</tbody>
</table>

<h3>About Gilead Sciences</h3>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Having examined the options trading patterns of Gilead Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Gilead Sciences</h3>
<ul>
<li>Trading volume stands at 3,825,036, with GILD's price up by 0.09%, positioned at $105.6.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Expert Opinions on Gilead Sciences</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $127.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $125. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Gilead Sciences with a target price of $130. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Gilead Sciences options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Gilead Sciences's Options Frenzy: What You Need to Know

Press Releases

Gilead Sciences to Present at Upcoming Investor Conferences

Gilead's Seladelpar Granted Conditional European Marketing Authorization for the Treatment of Primary Biliary Cholangitis

European Medicines Agency Validates Gilead's Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

First Clinical Data for Gilead's Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet

Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option

Center for Disease Analysis Foundation Awards Third Round of Grants for the CDAF Relink Program

Gilead Sciences to Release First Quarter 2025 Financial Results on Thursday, April 24, 2025

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer

Gilead Sciences Announces First Quarter 2025 Financial Results

Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

Comments

Gilead Sciences

Noticias

Últimas noticias sobre Gilead Sciences (NASDAQ:GILD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL